Drug Profile
RO 282653
Alternative Names: ROCHE 282653Latest Information Update: 19 Sep 2006
Price :
$50
*
At a glance
- Originator Roche
- Class Antineoplastics
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Prostate cancer
Most Recent Events
- 19 Sep 2006 Discontinued - Preclinical for Prostate cancer in Germany (unspecified route)
- 07 May 2003 Preclinical trials in Prostate cancer in Germany (unspecified route)